The firm recently took part in one of the earliest biosimilar disputes on behalf of Amgen. Following a two-week trial in the District of New Jersey, the asserted Amgen patent was upheld and three Sandoz subsidiaries were prevented from marketing their own biosimilar version of the drug Enbrel. The matter was recognized as one of Managing IP’s Impact Cases of the Year.
The group was also active for tech client CalAmp in a jury trial that resulted in a verdict of no willful infringement on all patents at suit. A previous award of $20 million that included attorneys’ fees and treble damages was then reduced to $4.6 million.
David Pritikin, one of the firm’s leading first-chair trial lawyers and a recognized IP Star, recently retired. This year he was awarded Outstanding Litigator in Illinois for his involvement in the high-profile biosimilar matter for Amgen.